AngioScore, Inc., a Fremont, California-based endovascular company, completed a $12m private equity financing.
The round was led by new investor Saints Capital, with participation from existing backers Psilos Group Managers, Telegraph Hill Partners, QuestMark Partners, Pelion Venture Partners, California Technology Ventures and Innomed Ventures.
In conjunction with the financing, Scott Halsted, Managing Director of Saints Capital, joined AngioScore’s Board of Directors.
As stated Thomas R. Trotter, president and CEO of the company, the funds will be used to continue to develop new products, which include:
– a 100mm AngioSculpt Scoring Balloon Catheter for treating peripheral artery disease;
a Drug Coated AngioSculpt Scoring Balloon Catheter;
– a specially designed AngioSculpt Scoring Balloon for Valvuloplasty and facilitation of Trans Aortic Valve Implantation (TAVI) procedures.